Lanfan Medical: Tongxin Medical's Left Ventricular Assist Device (Artificial Heart) in NMPA Registration Process

Source:Hithink RoyalFlushFinancial Research Center

On March 31, the Financial Research Center of Hithink RoyalFlush (300033) reported that an investor askedBluesail Medical(002382) Question: Hello, Board Secretary! Why is the company’s P/E ratio so high? Why is the share pledge ratio of the controlling shareholder also relatively high? In addition, according to reports, the fourth-generation artificial heart developed by BrioHealth Solutions, in which the company holds an equity stake, has shown promising clinical performance. When is it expected to be launched on the market, and what will be its impact on the company’s revenue?

The company responded: "Hello. The pledge by the major shareholder does not have a substantial impact on the listed company's production, operations, or corporate governance. It is understood that BrioHealth Solutions' left ventricular assist device (artificial heart) product is currently in the NMPA registration process; upon obtaining registration, it will be available for marketing and sales in China. Thank you for your attention."